Psoriasis
Podcasts
Continuing Medical Education
All News
Advertisement
More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.
Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.
At EULAR 2026, investigators presented head-to-head data demonstrating significantly higher joint response rates with bimekizumab compared with risankizumab in PsA.
Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.
Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.
Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.
New top-line results from the BE BOLD trial provide dermatology clinicians with comparative data on 2 biologic therapies targeting different inflammatory pathways in psoriatic arthritis (PsA).
Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.
Advertisement
Real-world data show IL-17 biologics rapidly improve special-site psoriasis and quality of life, as researchers identified predictors of PASI75/90 response.
New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis
2
SPD 2026: Phase 3 Success for Lebrikizumab in Younger Pediatric AD Patients
3
Tapinarof Cream Shows Consistent Response Across Pediatric AD Age Groups
4
Sunscreen’s New Blind Spot: Fashion Trends, Tanning Myths, and the Rise of Gluteal Melanomas
5